Long-Term Clinical Benefits of Canagliflozin 100 mg versus Sulfonylurea in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin in India

Long-Term Clinical Benefits of Canagliflozin 100 mg versus Sulfonylurea in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin in India

Objectives: To simulate the long-term health outcomes of canagliflozin 100 mg versus glimepiride over 20 years in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin from the perspective of the Indian health care system. Methods: Health outcomes were simulated using th...

Full description

Bibliographic Details
Main Authors: Gupta, V. (Author), Johansen, P. (Author), Mane, A. (Author), Neslusan, C. (Author), Nilsson, A. (Author), Shah, M. (Author), Willis, M. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2019
Subjects:
amputation
antidiabetic agent
Article
blindness
body mass
body weight
body weight gain
canagliflozin
Canagliflozin
cerebrovascular accident
chronic kidney failure
congestive heart failure
controlled study
Diabetes Mellitus, Type 2
diabetic foot
diabetic neuropathy
diabetic retinopathy
end stage renal disease
female
glimepiride
Glycated Hemoglobin A
glycosylated hemoglobin
health outcomes
heart infarction
hemoglobin A1c
hemoglobin A1c protein, human
hemoglobin blood level
human
Humans
hypoglycemia
Hypoglycemic Agents
incidence
India
ischemic heart disease
leg amputation
macroalbuminuria
macular edema
male
metformin
Metformin
microalbuminuria
modeling
morbidity
mycosis
non insulin dependent diabetes mellitus
priority journal
quality adjusted life year
risk reduction
SGLT2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors
standards
Sulfonylurea Compounds
sulfonylurea derivative
survival
systolic blood pressure
treatment outcome
Treatment Outcome
type 2 diabetes
urinary tract infection
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items